HK Stock Market Move | VISEN PHARMA-B(02561) rose more than 15% in early trading. The company has recently reached a project collaboration with Meghealth to explore new models of diverse payments.

VISEN PHARMA-B(02561) rose more than 15% in the morning session, rising 15.22% to HK$23.02 as of press time, with a turnover of HK$1.482 million. On the news front, Weishen Pharmaceutical recently announced a project cooperation with China's leading diversified medical and pharmaceutical payment platform, Meixin Health. Both parties will fully leverage their respective resource advantages in the field of innovative therapy and health services, jointly explore diverse paths to improve the accessibility and affordability of innovative therapies for endocrine diseases, and help Chinese patients benefit more conveniently from cutting-edge global treatment solutions. Chen Jun, Chief Business Officer of Weishen Pharmaceutical, stated, "Weishen Pharmaceutical has always been committed to introducing 'first-in-class' or 'best-in-class' innovative therapies into China. We not only want to make drugs available to patients, but also want to provide patients with good drugs. Weishen has leading global innovative endocrine therapies, while Meixin has rich practical experience in multiple payment areas. This cooperation will accelerate the reach of our innovative products to a broader patient base, truly achieving the leap from 'having drugs available' to 'being able to afford drugs'."